S-1/A: Invizyne Technologies Inc. Files Amendment No. 4 to Form S-1 for IPO

Invizyne Technologies Inc. has filed Amendment No. 4 to its Form S-1 registration statement, outlining details for its initial public offering and a secondary offering by a selling security holder.

Summary

• Invizyne Technologies Inc. has filed Amendment No. 4 to its Form S-1 registration statement with the SEC.
• The filing includes a prospectus for the initial public offering of 4,300,000 shares of common stock at a proposed price of $4.00 per share.
• It also includes a prospectus for the resale of 8,027,538 shares of common stock by MDB Capital Holdings, LLC, the company's majority shareholder.
• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• MDB Capital, a wholly owned subsidiary of MDB Capital Holdings, LLC, is acting as the underwriter for the offering, creating a conflict of interest that necessitates a qualified independent underwriter, Digital Offering LLC.
• The company is an emerging growth company and has taken advantage of certain reduced disclosure obligations.
• Net proceeds from the IPO are estimated at $15.3 million, or $17.7 million if the underwriter exercises its over-allotment option in full, and will be used for expansion, increasing staff, business development, R&D, and working capital.
• The company has received US government grants totaling $12,739,318 since inception.
• The company's primary commercialization strategy is to collaborate with third parties through out-licensing its technologies.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of Invizyne's technology and the risks associated with investing in a pre-revenue, development-stage company. The sentiment is neutral, focusing on factual information rather than overly optimistic or pessimistic projections.

Positives

• The company has received US government grants, particularly from the Department of Energy (DOE) and the National Institutes of Health (NIH), for work related to isobutanol and cannabinoids.
• The company's primary commercialization strategy is to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and product distribution.
• The company believes that its SimplePath platform performs the same conversions targeted by other cell engineering technologies.
• The company believes that the SimplePath platform and processes can be effective, less environmentally damaging or polluting, and more cost-effective than traditional methods, depending on the product that is being made.

Negatives

• Invizyne is a pre-revenue, development stage company with a limited operating history.
• The company anticipates needing additional funding in the future to continue developing its business plan.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements.
• The company's processes rely on the need for purified enzymes and co-factors, which are energy molecules, such as ATP or NADPH.
• The company is highly dependent on retaining the scientific staff and being able to hire additional scientific and related managerial staff.
• The company is subject to fluctuations in pricing for the products it chooses to develop and commercialize.

Risks

• The company may not be able to sustain its operations or become profitable in the future.
• The synthetic biological platform being developed by the company may not be able to develop a pipeline of commercial products.
• There may be regulatory hurdles that will have to be satisfied before the bio-synthesized compounds can be marketed and commercially used.
• Conditions in the laboratory setting may not be reproduced in a commercial setting.
• The company may face extensive competition from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways.
• The company may be unable to protect the intellectual property used in its technology platform and products.
• The company will incur increased costs as a result of operating as a public company.
• The company's Common Stock may potentially experience rapid and substantial price volatility, and price decline.
• The underwriter of this offering, MDB Capital, is a wholly owned subsidiary of MDB, the company's current majority shareholder and parent company, which may present a conflict of interest in respect of the offering.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of its capital stock in its private placement transactions to date.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds and with which you may not agree.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.

Future Outlook

The company intends to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development and technology platform and to add to working capital.

Industry Context

The announcement highlights Invizyne's position in the growing biomanufacturing industry, particularly in the production of chemicals for pharmaceuticals, fuels, and other sectors. It emphasizes the company's SimplePath platform as an alternative to traditional methods like chemical synthesis and natural extraction, aligning with the industry's shift towards sustainable and efficient production processes.

Comparison to Industry Standards

• Debut Biotech and Solugen Inc. promote the advantages of cell-free enzymatic systems over cell-based systems, but their processes appear to use simple one to two step pathways.
• Codexis, Inc. partnered with Tate & Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, such as enzymatic Islatravir synthesis, illustrating the potential for complex enzyme cascades, but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• There are many companies that focus on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd. (Singapore), Enzymit Ltd. (Israel and US), Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP (India).
• There are a number companies operating in the biofuels space, such as Valero Energy Corporation, ADM Corporation, Cargill Company, Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.

Related Party Transactions

• During 2023, MDB Capital Holdings, LLC provided the financial services of its chief financial officer to the Company.
• The value of these services was determined to be $95,000, which was charged to operations.
• The amount remains unpaid as of December 31, 2023.
• The Company has an intercompany payable to its parent company, MDB Capital, totaling $1,765,645 as of March 31, 2024.
• The payable balance consists of amounts related to audit fees, executive services, and an intercompany loan used for operations.

Stakeholder Impact

• Shareholders will experience immediate dilution in the book value per share of the Common Stock they purchase.
• The company's ability to attract and retain qualified personnel is important to the success of its business.
• The company's commercialization strategy is to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and product distribution.

Next Steps

• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• The company will continue to develop its SimplePath platform and processes to make its products for use in the pharmaceutical and biofuels industries.
• The company will seek to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and distribution as part of its commercialization strategy.

Key Dates

Keywords

IPO, initial public offering, biomanufacturing, SimplePath, enzymes, cannabinoids, isobutanol, biofuels, MDB Capital, Digital Offering LLC, emerging growth company, synthetic biology